Editorial
Copyright ©The Author(s) 2017.
World J Gastroenterol. May 14, 2017; 23(18): 3205-3213
Published online May 14, 2017. doi: 10.3748/wjg.v23.i18.3205
Table 2 Seroconversion rate in children and adolescents with celiac disease after intramuscular or intradermal hepatitis B virus vaccination
Ref.YearCountryStudy designPatients population and sample sizeVAC AgType of vaccineRouteNumber of boster dosesSeroconversion
Nemes et al[12]2008FinlandProspective37 (mean age, 16.7 yr) non responders CD on GFDHBVRecombinantIM197.30%
Ertem et al[13]2010TurkeyProspective28 (mean age ± SD, 12.4 ± 5.4 yr) non responders CDHBVRecombinantIM3 doses of HBV vaccine96.40%
Leonardi et al[55]2010ItalyProspective20 non responders CD to IM vaccinationHBVRecombinantID490%
Leonardi et al[56]2012ItalyProspective58 (mean age ± SD 9.8 ± 6.2 yr) non responders CDHBVRecombinant30 ID vs 28 IM3After first dose:
ID: 76.7% vs
IM: 78.6%
After third dose:
ID: 90% vs
IM: 96.4%
High responders
(anti-HBs > 1000 IU/L):
ID: 40%
IM: 7%, P < 0.01